Predicting the myelotoxicity of chemotherapy: The use of pretreatment O 6-methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cells

Melanoma Research

Volumn 21, Issue 6, 2011, Pages 502-508

  Sabharwal, Ami ^a   Waters, Rachel ^b   Danson, Sarah ^c   Clamp, Andrew ^c   Lorigan, Paul ^c   Thatcher, Nick ^c   Margison, Geoffrey P ^d   Middleton, Mark R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

dacarbazine; melanoma; O 6 methylguanine DNA methyltransferase; temozolomide; toxicity

Indexed keywords

DACARBAZINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PEGINTERFERON ALPHA2B; TEMOZOLOMIDE; THALIDOMIDE;

ADD ON THERAPY; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; DRUG CYTOTOXICITY; DRUG DOSE INCREASE; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MELANOMA; MULTIPLE CYCLE TREATMENT; PATIENT IDENTIFICATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, PHARMACOLOGICAL; DACARBAZINE; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; HUMANS; INTERFERON-ALPHA; LEUKOCYTES, MONONUCLEAR; MYELOID CELLS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; THALIDOMIDE; TIME FACTORS;

EID: 80955126743     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32832ccd58     Document Type: Article

References (25)

1. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 2004; 40:1825-1836.
2. Patel P, Suciu S, Mortier L, Kruit W, Robert C, Schadendorf D, et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV malignant melanoma: final results of the randomised phase III study (EORTC 18032). Ann Oncol 2008; 19 (Suppl 8):viii3.
3. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacabazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18:158-166.
4. Newlands ES, Stevens MFG, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997; 23:35-61.
5. Scudiero DA, Meyer SA, Clatterbuck BE, Mattern MR, Zloikowski CHJ, Day RS III. Sensitivity of human cell strains having different abilities to repair O6-methylguanine in DNA to inactivation by alkylating agents including chlorethyinitrosoureas. Cancer Res 1984; 44:2467-2474.
6. Friedman HS, Johnson SP, Dong Q, Schold SC, Rasheed BK, Bigner SH, et al. Methylator resistance mediated by mismatch reapir deficiency in a glioblastoma multiforme xenograft. Cancer Res 1997; 57:2933-2936.
7. Pegg AE, Dolan ME, Moschel RC. Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 1995; 51:167-223.
8. Tentori L, Orlando L, Lacal PM, Benincasa E, Faraoni I, Bonmassar E, et al. Inhibition of O6-alkylguanine-DNA alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide. Mol Pharmacol 1997; 52:249-258.
9. Jelinek J, Keibl K, Dexter T, Margison GP. Transfection of murine multipotent hemopoietic stem cells with an E. Coli DNA alkyltransferase gene onfersresistance to the toxic effects of alkylating agents. Carcinogenesis 1988; 9:81-87.
10. Middleton MR, Lunn JM, Morris C, Rustin G, Wedge SR, Brampton MH, et al. O6-methylguanine-DNA methyltransferase in pre-treatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer 1998; 78:1199-1202.
11. Ma S, Egyhá zi S, Ueno T, Lindholm C, Kreklau EL, Stierner U, et al. O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma. Br J Cancer 2003; 89:1517-1523.
12. Ranson M, Hersey P, Thompson D, Beith J, McArthur G, Haydon A, et al. A randomised trial of the combination of lomeguatrib and temozolomide and temozolomide alone in patients with advanced melanoma. J Clin Oncol 2007; 25:2540-2545.
13. Gajewski TF, Sosman J, Gerson SL, Liu L, Dolan E, Lin S, Vokes EE. Phase I trial of the O6-alkylguanine-DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. Clin Cancer Res 2005; 11:7861-7865.
14. Brock CS, Newlands ES,Wedge SR, Bower M, Evans H, Colquhoun I, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 1998; 58:4363-4367.
15. Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 2003; 88:1004-1011.
16. Gerson SL, Miller K, Berger NA. O6-alkylguanine-DNA alkyltransferase activity in human myeloid cells. J Clin Invest 1985; 76:2106-2114.
17. Middleton MR, Lorigan P, Owens J, Lee SM, Davies J, Yip B, et al. Dacarbazine, BCNU, cisplatin and tamoxifen versus dacarbazine and interferon in advanced melanoma: interim results of a phase III study. Br J Cancer 2000; 82:1158-1162.
18. Danson S, Lorigan P, Arance A, Clamp A, Ranson M, Hodgetts J, et al. A randomized phase II study of temozolomide given 8-hourly, or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol 2003; 21:2551-2557.
19. Middleton MR, Lee SM, Arance A, Wood M, Thatcher N, Margison GP. O6-methylguanine formation, repair protein depletion and clinical outcome with a 4-hourly schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study. Int J Cancer 2000; 88:469-473.
20. Watson AJ, Margison GP. O6-alkylguanine-DNA alkyltransferase assay. Methods Mol Biol 2000; 152:49-61.
21. Spiro TP, Gerson SL, Liu L, Majika S, Haaga J, Hoppel CL, et al. O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. Cancer Res 1999; 59:2402-2410.
22. D'Atri S, Piccioni D, Castellano A, Tuorto V, Franchi A, Lu K, et al. Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: studies with blasts of leukaemic patients. Ann Oncol 1995; 6:389-393.
23. Ranson M, Middleton MR, Bridgewater J, Lee SM, Dawson M, Jowle D, et al. Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA alkyltransferase: phase I safety, pharmacodynamic and phamacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2006; 12:1577-1584.
24. Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH, et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998; 16:1743-1751.
25. Bonfanti M, Taverna P, Mangioni C, Losa G, Taverna M, D'Incalci M. Interferon-b does not change the level of O6-alkylguanine-DNA alkyltransferase in cancer patients' lymphocytes. Anticancer Drugs 1994; 5:601-603.